It turns out that the regions greatest biotech research institutions like the National Institutes of Health in
and the Food and Drug Administration in White Oak may be part of the problem. Anirban
said it is a mindset problem that keeps the local biotech industry from
capitalizing on opportunities.
“When someone sneezes in
researchers try to figure out how to make a buck from it. When someone sneezes
in the Baltimore / Washington corridor researchers submit a grant to study it.”
Dr. Judy Britz is trying to change this. She is formerly the President and CEO of Cylex in
Columbia and now
serves as the Executive Director of the Maryland Biotechnology Center. She hopes to
alter this grant writing mindset by embedding private sector professionals in research departments who can
recognize commercial opportunities and capitalize on them.